PMC:7228307 / 2746-3199
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 35 | 50-71 | Disease | denotes | inflammatory diseases | MESH:D007249 |
| 36 | 84-91 | Disease | denotes | cancers | MESH:D009369 |
| 37 | 122-134 | Disease | denotes | malignancies | MESH:D009369 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T8 | 50-71 | Disease | denotes | inflammatory diseases | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T32 | 261-264 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T9 | 230-235 | Chemical | denotes | sales | http://purl.obolibrary.org/obo/CHEBI_24866 |
| T10 | 265-270 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T14 | 63-71 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | diseases |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 35 | 50-71 | Disease | denotes | inflammatory diseases | MESH:D007249 |
| 36 | 84-91 | Disease | denotes | cancers | MESH:D009369 |
| 37 | 122-134 | Disease | denotes | malignancies | MESH:D009369 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T20 | 0-453 | Sentence | denotes | They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T6 | 50-71 | Disease | denotes | inflammatory diseases | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T20 | 0-453 | Sentence | denotes | They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1 |